BiotechTube

Asceniv™

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Primary Immune Deficiency

Conditions

Primary Immune Deficiency

Trial Timeline

Sep 1, 2022 → Jun 30, 2023

NCT ID
NCT05070455

About Asceniv™

Asceniv™ is a approved stage product being developed by ADMA Biologics for Primary Immune Deficiency. The current trial status is unknown. This product is registered under clinical trial identifier NCT05070455. Target conditions include Primary Immune Deficiency.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05070455ApprovedUNKNOWN

Competing Products

20 competing products in Primary Immune Deficiency

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
22
azenosertibZentalis PharmaceuticalsPhase 2
44
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
77
REN001OnKure TherapeuticsPhase 1
25
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
44
REN001OnKure TherapeuticsPhase 2/3
57
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
44
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
52
Rituximab, lenalidomideCelltrionPhase 2
52
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
77
CS-3150Daiichi SankyoPre-clinical
23
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPre-clinical
23
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
Combination of bempedoic acid and ezetimibeDaiichi SankyoPre-clinical
23
DS-8201a + T-DM1Daiichi SankyoPhase 3
77
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
23
Roxadustat + PlaceboAstellas PharmaPhase 3
77
Enzalutamide + ExemestaneAstellas PharmaPhase 2
52
Bocidelpar + PlaceboAstellas PharmaPhase 2
52
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
52

Other Products from ADMA Biologics

BivigamApproved
80
Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]Phase 3
72
RI-002Phase 3
72
RI-001 + RI-001 + RI-001Phase 2
47
Hepatitis C Immune Globulin Intravenous (Human) 5%Phase 2
47